Hi, good evening, Rajeev and Rajesh. Rajeev, any particular launches you want to call out in the US for FY27 and '28?
Fair point. Fair point. And secondly, again, going back to Semaglutide, the fact that you have an FTF in the US. So, I am just a bit surprised why you are not pursuing opportunities in markets we are present like Canada, Brazil, now South Africa. So, just what is exactly happening there?